Strontium Complexes for Pain Relief via Antioxidant Merging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Strontium-based formulations face limitations in effectively inhibiting acute and chronic sensory irritation, pain, and neuropathic conditions due to their limited potency and negative effects on biochemical pathways, leading to incomplete pain relief and potential side effects.
Innovation Solution
Development of strontium-containing complexes with cysteine-based antioxidants and polyhydroxyphenols, which form bipartite or tripartite compositions, including a polymer, to enhance strontium's therapeutic potency by inhibiting nociceptor activation pathways and reducing osmolarity, thereby improving pain and pruritus management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topically applied strontium is used to inhibit sensory irritation and pain, then acute sensory irritation and inflammation are suppressed, but strontium activates biochemical pathways that enhance the development and maintenance of acute pain and neuropathic conditions
Solution Approach 1:
The patent combines strontium with polyhydroxyphenolic compounds and cysteine-based antioxidants to create a composite formulation. This merging allows the strontium's anti-irritant activity to be enhanced while the negative effects are counteracted by the additional components that inhibit the activated pain pathways.
Solution Approach 2:
The patent converts the harmful activation of biochemical pathways by strontium into a beneficial effect by adding components that specifically target and inhibit those same pathways. The harmful activation becomes an opportunity for enhanced therapeutic effect through the inhibitory components.
2Reliability
If strontium formulations are applied to treat neuropathic conditions, then some pain relief is achieved, but the therapeutic potency is insufficient and side effects occur
Solution Approach 1:
The patent creates a composite formulation combining strontium with polyhydroxyphenolic compounds and cysteine-based antioxidants. This composite approach enhances therapeutic potency by leveraging the synergistic effects of multiple components while managing side effects through the specific functional contributions of each ingredient.
3Reliability
If strontium is used to suppress nociceptor activation, then sensory irritation is reduced, but the potency is limited and incomplete pain relief is achieved
Solution Approach 1:
The patent merges strontium with polyhydroxyphenolic compounds and cysteine-based antioxidants to create a multi-component system. This combination achieves greater therapeutic potency than strontium alone by adding components that contribute additional mechanisms of pain relief and inflammation reduction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The strontium complexes effectively inhibit acute and chronic sensory irritation, pain, and neuropathic conditions by amplifying strontium's anti-irritant activity, reducing side effects, and providing sustained therapeutic benefits with minimal osmotic activity, thus offering enhanced pain relief and pruritus management.
Implementation Method 1
strontium-containing complexes with cysteine-based antioxidants and polyhydroxyphenols, which form bipartite or tripartite compositions
Implementation Method 2
reducing osmolarity, thereby improving pain and pruritus management
Data Source
AI summary
Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.